Blood Test Can Predict Severity of COVID-19
By LabMedica International staff writers Posted on 30 Jun 2020 |
Illustration
Doctors can now identify COVID-19 patients having the highest risk of severe illness and pinpoint those most likely to need a ventilator by simply examining their blood.
This discovery by researchers from the University of Virginia (UVA) School of Medicine (Charlottesville, VA, USA) could lead to new treatments for the prevention of deadly “cytokine storms” seen in severe cases of COVID-19. It also may help explain why diabetes contributes to worse outcomes in patients with the coronavirus.
Cytokines – proteins produced by immune cells – are responsible for severe overreactions by the immune system, known as cytokine storms, associated with COVID-19 and other serious illnesses. Cytokine storms are typically associated with an established group of cytokines. The researchers identified 57 COVID-19 patients treated at UVA who ultimately required a ventilator and then tested their blood samples within 48 hours of diagnosis or hospital admission. They compared the results with those from patients who did not end up needing a ventilator. The researchers found that the best predictor of COVID-19 outcomes was an “underappreciated” cytokine more associated with allergies. High levels of that cytokine, IL-13, were associated with worsened COVID-19 outcomes regardless of patients’ gender, age or other health problems.
The researchers also identified two more cytokines associated with severe outcomes, though the duo had less ability to predict the need for a ventilator. The researchers say the discovery could become part of a scoring system to let doctors flag up at-risk COVID-19 patients for closer monitoring and personalized interventions. In addition, the researchers found that levels of two other cytokines were significantly higher in patients with elevated blood sugar. This “proinflammatory response” could help explain why diabetes is associated with worse COVID-19 outcomes, according to the researchers.
“The immune response that we discovered to predict severe shortness of breath in COVID-19 is known in other pulmonary diseases to cause damage. So this could lead to a novel way to prevent respiratory failure in individuals infected with the new coronavirus, by inhibiting this immune cytokine,” said Bill Petri, MD, PhD, of UVA’s Division of Infectious Diseases and International Health. “We plan to test this in a model of COVID-19 prior to considering a clinical trial.”
Related Links:
University of Virginia School of Medicine
This discovery by researchers from the University of Virginia (UVA) School of Medicine (Charlottesville, VA, USA) could lead to new treatments for the prevention of deadly “cytokine storms” seen in severe cases of COVID-19. It also may help explain why diabetes contributes to worse outcomes in patients with the coronavirus.
Cytokines – proteins produced by immune cells – are responsible for severe overreactions by the immune system, known as cytokine storms, associated with COVID-19 and other serious illnesses. Cytokine storms are typically associated with an established group of cytokines. The researchers identified 57 COVID-19 patients treated at UVA who ultimately required a ventilator and then tested their blood samples within 48 hours of diagnosis or hospital admission. They compared the results with those from patients who did not end up needing a ventilator. The researchers found that the best predictor of COVID-19 outcomes was an “underappreciated” cytokine more associated with allergies. High levels of that cytokine, IL-13, were associated with worsened COVID-19 outcomes regardless of patients’ gender, age or other health problems.
The researchers also identified two more cytokines associated with severe outcomes, though the duo had less ability to predict the need for a ventilator. The researchers say the discovery could become part of a scoring system to let doctors flag up at-risk COVID-19 patients for closer monitoring and personalized interventions. In addition, the researchers found that levels of two other cytokines were significantly higher in patients with elevated blood sugar. This “proinflammatory response” could help explain why diabetes is associated with worse COVID-19 outcomes, according to the researchers.
“The immune response that we discovered to predict severe shortness of breath in COVID-19 is known in other pulmonary diseases to cause damage. So this could lead to a novel way to prevent respiratory failure in individuals infected with the new coronavirus, by inhibiting this immune cytokine,” said Bill Petri, MD, PhD, of UVA’s Division of Infectious Diseases and International Health. “We plan to test this in a model of COVID-19 prior to considering a clinical trial.”
Related Links:
University of Virginia School of Medicine
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants